Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 7/20 | 0.35 |
| ▸ | TNF | P01375 | 6/20 | 0.35 |
| ▸ | RAB9A | P51151 | 5/20 | 0.35 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | NR2F2 | P24468 | 3/20 | 0.35 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.35 |
| ▸ | GALR3 | O60755 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14637660 | 0.84 | SIGMAR1 (0.43) | PLK1CSNK2A1PLK3SIGMAR1GFER | |
| SCHEMBL3143484 | 0.82 | PLK1 (0.49) | PLK1CSNK2A1PLK3CNR2 | |
| SCHEMBL19643518 | 0.75 | MAPK1 (0.35) | — | |
| SCHEMBL24015507 | 0.74 | NOD1 (0.48) | GFERATMKMT2ANOD1TNF | |
| SCHEMBL19656987 | 0.74 | AHR (0.36) | GFERKMT2AMEN1 | |
| SCHEMBL15905254 | 0.73 | SIGMAR1 (0.44) | PLK1CSNK2A1PLK3SIGMAR1GFER | |
| SCHEMBL19656906 | 0.71 | LMNA (0.35) | RAB9ANPC1CNR2 | |
| SCHEMBL25587329 | 0.71 | NOD1 (0.49) | GFERATMKMT2ANOD1TNF | |
| SCHEMBL4572408 | 0.71 | SIGMAR1 (0.45) | PLK1CSNK2A1PLK3SIGMAR1GFER | |
| SCHEMBL22492369 | 0.71 | F12 (0.43) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2948431-B1 | BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2019-03-13 | — | — | EP | disclosed |
| EP-2734529-B1 | BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-09-05 | — | — | EP | disclosed |
| US-9718828-B2 | BTK Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170008899-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| US-9446130-B2 | BTK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20150353565-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
| EP-2948431-A1 | BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-12-02 | — | — | EP | disclosed |
| US-20140221333-A1 | BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-08-07 | — | — | US | disclosed |
| WO-2014116504-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-07-31 | — | — | WO | disclosed |
| WO-2014113942-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-07-31 | — | — | WO | disclosed |
| EP-2734529-A1 | BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-05-28 | — | — | EP | disclosed |
| WO-2013010380-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353565-A1 | BTK INHIBITORS | BTK, SYK, LYN | PLK1 309/4885CSNK2A1 94/4885PLK3 1280/4885 |
| US-20170008899-A1 | BTK INHIBITORS | BTK, SYK, ABL1 | PLK1 282/4885CSNK2A1 154/4885PLK3 1094/4885 |
| US-20140221333-A1 | BTK INHIBITORS | BTK, SYK, ABL1 | PLK1 280/4885CSNK2A1 153/4885PLK3 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.